NEWARK, DE — Wilmington PharmaTech announced it will invest $50 million to expand its Delaware campus, increasing manufacturing capacity to meet demand for U.S.-based production of pharmaceutical ingredients.
The expansion will add two 10,000-liter reactor suites, more than doubling the company’s current active pharmaceutical ingredient production capacity.
The new facilities are expected to come online in the third quarter of 2027, and the company said it plans to approximately double its workforce at the site upon completion.
Wilmington said the project is part of a multi-year strategy to expand domestic manufacturing capabilities and follows the recent addition of suites for highly potent active pharmaceutical ingredients.
Hui-Yin “Harry” Li, founder and chief executive officer, said the investment builds on the company’s existing manufacturing infrastructure.
“This expansion builds on more than 20 years of cGMP manufacturing expertise and further strengthens our ability to address complex chemistry challenges at scale,” Li said.
Kent Payne, operating partner at Curewell Capital and managing director at Wilmington PharmaTech, said the expansion is intended to support domestic production capacity.
“We believe Wilmington is uniquely positioned to serve biopharmaceutical innovators with reliable, scalable domestic production, helping to bolster supply chain resilience,” Payne said.
The company operates two manufacturing facilities on a 54-acre campus in Newark, with additional development and analytical operations in Suzhou, China.
Wilmington PharmaTech provides research, development and manufacturing services for small molecule pharmaceutical compounds across clinical and commercial stages.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.